1-[3-(4-iodophenoxy)propyl]-1H-1,2,4-triazole | 1449769-04-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 1-[3-(4-iodophenoxy)propyl]-1H-1,2,4-triazole
• 英文别名: 1-[3-(4-Iodophenoxy)propyl]-1,2,4-triazole；1-[3-(4-iodophenoxy)propyl]-1,2,4-triazole
• CAS: 1449769-04-3
• 化学式: C₁₁H₁₂IN₃O
• 分子量: 329.14
• InChiKey: SCCIDSYLKBREGC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  39.9
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  4-碘苯酚 在 四丁基溴化铵 、 potassium carbonate 、 三乙胺 作用下， 以 丙酮 、 乙腈 为溶剂， 90.0~100.0 ℃ 、1.03 MPa 条件下， 反应 45.5h， 生成 1-[3-(4-iodophenoxy)propyl]-1H-1,2,4-triazole
  参考文献：
  名称：

  Evaluation of novel aryloxyalkyl derivatives of imidazole and 1,2,4-triazole as heme oxygenase-1 (HO-1) inhibitors and their antitumor properties

  摘要：

  A novel series of aryloxyalkyl derivatives of imidazole and 1,2,4-triazole, 17-31, was designed and synthesized as inhibitors of heme oxygenase-1 (HO-1) and heme oxygenase-2 (HO-2). Some of these compounds were found to be good inhibitors of HO-1, in particular those carrying an imidazole moiety as azolyl group and a 3-bromo or 4-iodophenyl as aryl moiety. The most potent compounds 6 and 30 were selected and studied for their antitumor properties in a model of LAMA-84 R cell line overexpressing HO-1 and resistant to imatinib mesylate (IM), a tyrosine-kinase inhibitor used in the treatment of multiple types of cancer, most notably Philadelphia Chromosome positive (Ph+) Chronic Myelogenous Leukemia (CML). Results show that both 6 and 30 sensitized LAMA-84 R cell line to antitumor properties of IM. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2013.06.040

文献信息

• TETRACYCLIC CARBOLINE DERATIVES FOR INHIBITING ANGIOGENESIS
  申请人：PTC Therapeutics, Inc.

  公开号：EP1732543B1

  公开（公告）日：2017-05-10
• [EN] CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES<br/>[FR] DÉRIVÉS DE CARBOLINE UTILISÉS DANS LE TRAITEMENT DU CANCER ET AUTRES MALADIES
  申请人：PTC THERAPEUTICS INC

  公开号：WO2008127715A1

  公开（公告）日：2008-10-23

  [EN] In accordance with the present invention, compounds are provided which are useful in a method or in the manufacture of a medicament for post-transcriptionally inhibiting the expression of VEGF in a subject in need thereof comprising inhibiting pathologically induced expression of VEGF without suppressing normal physiological VEGF expression by inhibiting pathologically induced VEGF mRNA translation without causing a statistically significant suppression of normal physiological VEGF mRNA translation.
  [FR] La présente invention concerne des composés utilisés dans un procédé ou dans la fabrication d'un médicament visant à inhiber de manière post-transcriptionnelle l'expression du facteur de croissance de l'endothélium vasculaire (VEGF) chez un sujet nécessitant un tel traitement, ledit procédé consistant à inhiber l'expression pathologiquement induite du facteur de croissance VEGF sans en supprimer l'expression physiologique normale en inhibant la traduction pathologiquement induite de l'ARNm du facteur de croissance VEGF sans entraîner de suppression statistiquement significative de la traduction physiologique normale de l'ARNm du facteur de croissance VEGF.
• Evaluation of novel aryloxyalkyl derivatives of imidazole and 1,2,4-triazole as heme oxygenase-1 (HO-1) inhibitors and their antitumor properties
  作者：Loredana Salerno、Valeria Pittalà、Giuseppe Romeo、Maria N. Modica、Maria A. Siracusa、Claudia Di Giacomo、Rosaria Acquaviva、Ignazio Barbagallo、Daniele Tibullo、Valeria Sorrenti

  DOI：10.1016/j.bmc.2013.06.040

  日期：2013.9

  A novel series of aryloxyalkyl derivatives of imidazole and 1,2,4-triazole, 17-31, was designed and synthesized as inhibitors of heme oxygenase-1 (HO-1) and heme oxygenase-2 (HO-2). Some of these compounds were found to be good inhibitors of HO-1, in particular those carrying an imidazole moiety as azolyl group and a 3-bromo or 4-iodophenyl as aryl moiety. The most potent compounds 6 and 30 were selected and studied for their antitumor properties in a model of LAMA-84 R cell line overexpressing HO-1 and resistant to imatinib mesylate (IM), a tyrosine-kinase inhibitor used in the treatment of multiple types of cancer, most notably Philadelphia Chromosome positive (Ph+) Chronic Myelogenous Leukemia (CML). Results show that both 6 and 30 sensitized LAMA-84 R cell line to antitumor properties of IM. (C) 2013 Elsevier Ltd. All rights reserved.